SCHEMBL1493568

SCHEMBL1493568

CCOC(=O)CCCOc1ccccc1N1CCN(C(=O)O)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.52
GAA P10253 3/20 0.52
HTR1A P08908 1/20 0.52
HTR7 P34969 1/20 0.52
SMN1; SMN2 Q16637 5/20 0.51
KMT2A Q03164 7/20 0.49
MEN1 O00255 6/20 0.49
MAPT P10636 6/20 0.49
APAF1 O14727 1/20 0.49
LMNA P02545 1/20 0.49
TSHR P16473 3/20 0.48
NPSR1 Q6W5P4 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
HTT P42858 2/20 0.48
MAPK1 P28482 2/20 0.48
USP2 O75604 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3260753 0.87 SMN1; SMN2 (0.51) PKML3MBTL1GAAHTR1AHTR7
SCHEMBL1491176 0.87 SMN1; SMN2 (0.51) PKML3MBTL1GAAHTR1AHTR7
SCHEMBL3157375 0.85 HTR1A (0.51) PKML3MBTL1GAAHTR1AKMT2A
SCHEMBL3157870 0.83 DRD2 (0.61) HTR1AHTR7KMT2AMEN1ALDH1A1
SCHEMBL7334443 0.83 SMN1; SMN2 (0.56) PKML3MBTL1GAAHTR1AHTR7
SCHEMBL7403379 0.80 SMN1; SMN2 (0.55) PKML3MBTL1GAAHTR1AHTR7
SCHEMBL253112 0.79 L3MBTL1 (0.64) L3MBTL1GAAHTR1AHTR7SMN1; SMN2
SCHEMBL11630844 0.77 HTR1A (0.67) L3MBTL1HTR1AHTR7SMN1; SMN2KMT2A
SCHEMBL26473528 0.77 DRD2 (0.56) L3MBTL1GAAHTR1AHTR7KMT2A
SCHEMBL1491170 0.75 DRD2 (0.67) PKMHTR1AHTR7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247420-B2 Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents REVIVA PHARMACEUTICALS, INC. (US) 2012-08-21 US disclosed
EP-2299814-A1 COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS Reviva Pharmaceuticals, Inc. (US) 2011-03-30 EP disclosed
EP-2162135-A1 COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS Reviva Pharmaceuticals, Inc. (US) 2010-03-17 EP disclosed
WO-2009154993-A1 COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS REVIVA PHARMACEUTICALS, INC. (US) 2009-12-23 WO disclosed
WO-2008144764-A1 COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS REVIVA PHARMACEUTICALS, INC. (US) 2008-11-27 WO disclosed
US-20080293736-A1 Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents REVIVA PHARMACEUTICALS, INC. (US) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293736-A1 Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents GRIN2D, GRIN2C, AP3D1 PKM 3967/4885L3MBTL1 4727/4885GAA 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.